EP Patent

EP1796642A1 — New pharmaceutical compositions for the treatment of cancer

Assigned to Bayer Pharmaceuticals Corp · Expires 2007-06-20 · 19y expired

What this patent protects

This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as …

USPTO Abstract

This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I is as follows:

Drugs covered by this patent

Patent Metadata

Patent number
EP1796642A1
Jurisdiction
EP
Classification
Expires
2007-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharmaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.